Literature DB >> 28778325

Mite allergoids coupled to nonoxidized mannan from Saccharomyces cerevisae efficiently target canine dendritic cells for novel allergy immunotherapy in veterinary medicine.

Irene Soria1, Javier Alvarez2, Ana I Manzano3, Juan López-Relaño4, Bárbara Cases1, Ana Mas-Fontao2, F Javier Cañada5, Enrique Fernández-Caldas6, Miguel Casanovas1, Jesús Jiménez-Barbero7, Oscar Palomares8, Luis M Viñals-Flórez9, José L Subiza10.   

Abstract

We have recently reported that grass pollen allergoids conjugated with nonoxidized mannan of Saccharomyces cerevisae using glutaraldehyde results in a novel hypoallergenic mannan-allergen complex with improved properties for allergen vaccination. Using this approach, human dendritic cells show a better allergen uptake and cytokine profile production (higher IL-10/IL-4 ratio) for therapeutic purposes. Here we aim to address whether a similar approach can be extended to dogs using canine dendritic cells. Six healthy Spanish Greyhound dogs were used as blood donors to obtain canine dendritic cells (DC) derived from peripheral blood monocytes. Allergens from Dermatophagoides farinae mite were polymerized and conjugated with nonoxidized mannan. Nuclear magnetic resonance (NMR), gel electrophoresis (SDS-PAGE), immunoblotting and IgE-ELISA inhibition studies were conducted to evaluate the main characteristics of the allergoid obtained. Mannan-allergen conjugate and controls were assayed in vitro for canine DC uptake and production of IL-4 and IL-10. The results indicate that the conjugation of D. farinae allergens with nonoxidized mannan was feasible using glutaraldehyde. The resulting product was a polymerized structure showing a high molecular weight as detected by NMR and SDS-PAGE analysis. The mannan-allergen conjugate was hypoallergenic with a reduced reactivity with specific dog IgE. An increase in both allergen uptake and IL-10/IL-4 ratio was obtained when canine DCs were incubated with the mannan-allergen conjugate, as compared with the control allergen preparations (unmodified D. farinae allergens and oxidized mannan-allergen conjugate). We conclude that hypoallergenic D. farinae allergens coupled to nonoxidized mannan is a novel allergen preparation suitable for canine allergy immunotherapy targeting dendritic cells.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28778325     DOI: 10.1016/j.vetimm.2017.07.004

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  5 in total

1.  Oral myeloid cells uptake allergoids coupled to mannan driving Th1/Treg responses upon sublingual delivery in mice.

Authors:  I Soria; J López-Relaño; M Viñuela; J-I Tudela; A Angelina; C Benito-Villalvilla; C M Díez-Rivero; B Cases; A I Manzano; E Fernández-Caldas; M Casanovas; O Palomares; J L Subiza
Journal:  Allergy       Date:  2018-01-31       Impact factor: 13.146

Review 2.  Novel vaccines targeting dendritic cells by coupling allergoids to mannan.

Authors:  Cristina Benito-Villalvilla; Irene Soria; José Luis Subiza; Oscar Palomares
Journal:  Allergo J Int       Date:  2018-05-18

3.  Alum impairs tolerogenic properties induced by allergoid-mannan conjugates inhibiting mTOR and metabolic reprogramming in human DCs.

Authors:  Cristina Benito-Villalvilla; Irene Soria; Mario Pérez-Diego; Enrique Fernández-Caldas; José Luis Subiza; Oscar Palomares
Journal:  Allergy       Date:  2019-10-03       Impact factor: 13.146

Review 4.  C-Type Lectins in Veterinary Species: Recent Advancements and Applications.

Authors:  Dimitri Leonid Lindenwald; Bernd Lepenies
Journal:  Int J Mol Sci       Date:  2020-07-20       Impact factor: 5.923

Review 5.  Formulations for Allergen Immunotherapy in Human and Veterinary Patients: New Candidates on the Horizon.

Authors:  Isabella Pali-Schöll; Douglas J DeBoer; Claudia Alessandri; Ahmed Adel Seida; Ralf S Mueller; Erika Jensen-Jarolim
Journal:  Front Immunol       Date:  2020-08-04       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.